Area of research
Hematology · Oncology
Research interest
Research interests include Medicine, Internal medicine, Tolerability, Azacitidine, Rituximab, and Adverse effect.
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Transfusion management in the era of magrolimab (<scp>Hu5F9‐G4</scp>), an anti‐<scp>CD47</scp> monoclonal antibody therapy
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.